HAVCR2 and metastatic neoplasm: Subsequent survival analysis, as shown in Fig. 2a-b, suggested that TIM-3 expression either in the primary or metastatic tumor was associated with longer PFS (HR: 0.67, 95% CI 0.45–0.99, P = 0.02) and OS (HR: 0.52, 95% CI 0.33–0.82, P < 0.001).